Clinical Trial Update: 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing lutetium-177-PSMA-617 to docetaxel in metastatic castration-resistant, PSMA-positive prostate cancer; the study is active but not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING